The Cost of Poor Specimen Quality and Errors in Preanalytical Processes

 

Wednesday, August 7, 10:15 – 11:15 a.m.
Exhibit Hall, Theater 2
Supported by BD

Overview

The increase in the prevalence of medical errors represents a disturbing trend; hospital-based errors are the eighth leading cause of death in the United States. For the clinical laboratory, errors that occur in the preanalytical phase of testing may account for up to 75% of total laboratory errors; 26% of these may have detrimental effects on patient care, which contribute to unnecessary investigations, inappropriate treatment, increases in the length of hospital stays, as well as dissatisfaction with healthcare services. This workshop focuses on these errors, particularly those observed in the preanalytical phase, and how they may affect clinical and financial outcomes.

Outcomes

Attendees will:

  • Understand the cost implications of preanalytical errors.
  • Learn to mitigate the impact of these costly errors by complying with best practices for sample handling and processing to ensure high quality specimens.

Speakers

Sol Green, PhD, FAACC
Director, Medical Affairs
BD Life Sciences—Preanalytical Systems
Franklin Lakes, NJ

Jennifer Dawson, MHA, FACHE, LSSBB, CPHQ, DLM (ASCP) SLS, QIHC, QLC
Vice President, Quality & Regulatory
Human Longevity Inc.
San Diego, CA

Valerie Wassenaar
Improvement Specialist
Spectrum Health
Grand Rapids, MI